Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)
Bluebird Bio's Hold Rating: Balancing Commercial Progress With Financial Restatements and Investor Concerns
Bluebird Bio Analyst Ratings
Wells Fargo Maintains Equal-Weight on Bluebird Bio, Lowers Price Target to $3
Bluebird Bio (BLUE) Receives a Hold From RBC Capital
Buy Rating Upheld for Bluebird Bio Amidst Revenue Miss and Promising Gene Therapy Launch
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Healthequity (HQY) and Bluebird Bio (BLUE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
Hold Rating on Bluebird Bio Amidst Gradual Patient Starts and Funding Steps
Wedbush Adjusts Bluebird Bio Price Target to $1.72 From $1.68, Maintains Neutral Rating
Optimistic Outlook for Bluebird Bio: Buy Rating Affirmed on Extended Financial Runway and Profitability Prospects
Bluebird Bio Analyst Ratings
Wedbush Maintains Neutral on Bluebird Bio, Lowers Price Target to $1.68
Wedbush Adjusts Bluebird Bio's Price Target to $1.68 From $3, Maintains Neutral Rating
Bluebird Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Alcon (ALC)
Market Perform Rating Maintained for Bluebird Bio Amidst New Therapy Launch and Financial Uncertainty
Hold Rating on Bluebird Bio Amid Launch Optimism and Financial Prudence
William Blair Reaffirms Their Hold Rating on Bluebird Bio (BLUE)
No Data